Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Angioimmunoblastic T-cell Lymphoma (AITL)”

21 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 21 results

Testing effectiveness (Phase 2)Looking for participantsNCT07058103
What this trial is testing

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of R/R AITL

Who this might be right for
Angioimmunoblastic T-Cell Lymphoma RecurrentAngioimmunoblastic T-Cell Lymphoma Refractory
The Affiliated Hospital of Xuzhou Medical University 40
Testing effectiveness (Phase 2)Ended earlyNCT04251065
What this trial is testing

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Who this might be right for
Refractory T-Cell LymphomaRelapsed T-Cell Lymphoma
Fondazione Italiana Linfomi - ETS 8
Post-approval studies (Phase 4)Active Not RecruitingNCT07046182
What this trial is testing

Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma Foresight

Who this might be right for
Angioimmunoblastic T-cell Lymphoma (AITL)
Zhengzhou University 34
Testing effectiveness (Phase 2)Study completedNCT02273739
What this trial is testing

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Who this might be right for
Solid TumorGliomaAngioimmunoblastic T-cell Lymphoma+2 more
Celgene 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT02223208
What this trial is testing

Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas

Who this might be right for
Peripheral T-cell Lymphomas (PTCL)PTCL-NOSAngioimmunoblastic T-cell Lymphoma (AITL)+2 more
Fondazione Italiana Linfomi - ETS 89
Testing effectiveness (Phase 2)UnknownNCT06224842
What this trial is testing

Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITL

Who this might be right for
Angioimmunoblastic T-cell Lymphoma
Huijing Wu 30
Large-scale testing (Phase 3)Not Yet RecruitingNCT07300514
What this trial is testing

Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma

Who this might be right for
Peripheral T-Cell Lymphoma (PTCL NOS)Anaplastic Large Cell Lymphoma, ALK-NegativeAngioimmunoblastic T-cell Lymphoma (AITL)+1 more
Fudan University 136
Large-scale testing (Phase 3)WithdrawnNCT04021082
What this trial is testing

CELTIC-1: A Phase 2B Study of Cerdulatinib in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma (PTCL)

Who this might be right for
Peripheral T-Cell Lymphoma (PTCL NOS)Nodal Lymphomas of T Follicular Helper (TFH)Follicular T-cell Lymphoma (FTCL)+6 more
Portola Pharmaceuticals
Testing effectiveness (Phase 2)Temporarily pausedNCT06692452
What this trial is testing

Tazemetostat Plus CHOP in 1L T-cell Lymphoma

Who this might be right for
LymphomaPeripheral T Cell LymphomaAngioimmunoblastic T-cell Lymphoma+2 more
Eric Jacobsen, MD 24
Large-scale testing (Phase 3)Active Not RecruitingNCT03593018
What this trial is testing

Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients with Relapsed or Refractory AITL

Who this might be right for
Relapsed Angioimmunoblastic T-Cell LymphomaRefractory Angioimmunoblastic T-cell Lymphoma
The Lymphoma Academic Research Organisation 86
Large-scale testing (Phase 3)Looking for participantsNCT06561048
What this trial is testing

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Who this might be right for
Peripheral T-Cell Lymphoma, Not Otherwise SpecifiedAngioimmunoblastic T-cell LymphomaFollicular T-Cell Lymphoma+4 more
Corvus Pharmaceuticals, Inc. 150
Testing effectiveness (Phase 2)Temporarily pausedNCT06761677
What this trial is testing

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Who this might be right for
Relapsed or Refractory Lymphoma Including ENKL
SymBio Pharmaceuticals 43
Testing effectiveness (Phase 2)Ended earlyNCT03552692
What this trial is testing

Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Who this might be right for
T-Cell Lymphoma RelapsedT-Cell Lymphoma Refractory
Fondazione Italiana Linfomi - ETS 22
Testing effectiveness (Phase 2)Looking for participantsNCT07168317
What this trial is testing

Tislelizumab , Cyclophosphamide, Mitoxantrone Liposomes, Chidamide, and Prednisone in the Treatment of New Diagnosed AITL

Who this might be right for
New Diagnosed Angioimmunoblastic T-Cell Lymphoma
The Affiliated Hospital of Xuzhou Medical University 40
Testing effectiveness (Phase 2)Study completedNCT01553786
What this trial is testing

Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)

Who this might be right for
T-cell Lymphoma
The Lymphoma Academic Research Organisation 80
Early research (Phase 1)Looking for participantsNCT04234048
What this trial is testing

Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma

Who this might be right for
T-cell LymphomaCutaneous/Peripheral T-Cell LymphomaPeripheral T-cell Lymphoma+8 more
SciTech Development, Inc. 46
Early research (Phase 1)Active Not RecruitingNCT02520791
What this trial is testing

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

Who this might be right for
Advanced Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeRecurrent Grade 1 Follicular Lymphoma+16 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)UnknownNCT04831710
What this trial is testing

Sintilimab in Combination With Chidamide in Refractory and Relapsed AITL

Who this might be right for
Angioimmunoblastic T-cell Lymphoma
Sun Yat-sen University 83
Testing effectiveness (Phase 2)Looking for participantsNCT06035497
What this trial is testing

Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Who this might be right for
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb 85
Early research (Phase 1)Looking for participantsNCT06393738
What this trial is testing

ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Who this might be right for
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc. 255
Load More Results
21